Q-omics provides the consensus-scored HSPB7 profile across patient tissues and cancer cell-line models. HSPB7 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, HSPB7 is differentially expressed in 17, with the highest sampling consensus in KIRC. Additionally, HSPB7 protein abundance shows 25,543 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, KIRC, and LSCC as cancer lineages where HSPB7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HSPB7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HSPB7 survival associations across molecular data types. HSPB7 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HSPB7 RNA expression–survival associations across cancer types. High HSPB7 expression shows unfavorable associations in BLCA, OV, HNSC, LGG and LUSC, but favorable associations in ACC. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for HSPB7 RNA expression.
This table summarizes HSPB7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for HSPB7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HSPB7 shows lower tumor expression in KIRC, BLCA, LUAD, THCA, KIRP and LUSC. The KIRC box plot shows higher HSPB7 RNA expression in normal versus tumor tissue (log2 FC = −3.703, t-test p < 0.001).
This table shows molecular features associated with HSPB7 in patient tissues and cancer cell lines. In patient samples, HSPB7 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, HSPB7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BONE.
